INVEST SECURITIES - Quantum : Accélération des développements cliniques - ACHAT ; OC 9,6€
Hier soir, Quantum Genomics a organisé une revue stratégique de son portefeuille clinique. Nous retenons 3 principaux points : (i) le recrutement de NEW HOPE s'est accéléré et la fin de l'étude est prévue 6 mois plus tôt, (ii) un lancement d'une phase IIb dans l'insuffisance cardiaque est prévu dès cette année et (iii) la volonté du management de trouver un partenariat d'ici à 24 mois afin de prendre en charge les essais de phases III à grande échelle. Suite à cette revue nous ne modifions pas pour l'instant notre OC mais maintenons notre recommandation à ACHAT. Le titre devrait bien réagir ce matin.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.